Physician profile
Kara Fiore
NPI 1972226926
$979.93
in general payments reported to CMS, 2019-2025
12 companies · $864 in 2025
The $864 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $116 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.67 |
| Education | $174.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $355.77 | 2025 | Tremfya |
| Abbvie INC. | $238.07 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $117.72 | 2025 | Dupixent |
| Ucb, INC. | $85.15 | 2024 | Bimzelx |
| Verrica Pharmaceuticals INC. | $46.86 | 2025 | Ycanth |
| Organon LLC | $34.74 | 2025 | Vtama |
| Incyte Corporation | $20.78 | 2025 | Opzelura |
| Lilly USA, LLC | $20.00 | 2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $16.39 | 2025 | Sotyktu |
| Pfizer INC. | $15.09 | 2024 | |
| Galderma Laboratories, L.P. | $15.00 | 2025 | |
| Sun Pharmaceutical Industries INC. | $14.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.